COMMUNIQUÉS West-GlobeNewswire

-
HealthSure 3X Launches Virtual In-Home Medical Services with Improved Access to Quality Care
24/07/2025 -
Biodesix to Report Second Quarter 2025 Financial Results on August 7, 2025
24/07/2025 -
MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials
24/07/2025 -
Javvy Protein Coffee Officially Launches, Redefining Javy Coffee Protein United States & Canada
24/07/2025 -
Biomea Fusion Appoints Julianne Averill to its Board of Directors
24/07/2025 -
INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro™ at the Alzheimer’s Association International Conference
24/07/2025 -
TCG Labs Soleil Raises an Additional $400 Million and Expands Global R&D Capabilities
24/07/2025 -
Award-Winning Breckenridge Distillery Makes Bold Entry into Tequila with Launch of Casa Breck
24/07/2025 -
Microbix Exhibiting & Presenting at ADLM
24/07/2025 -
Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results
24/07/2025 -
Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025
24/07/2025 -
MediPharm Labs Expands Leading CBN Oil Portfolio with The Launch of New Nighttime Inhaler
24/07/2025 -
Cannara obtient 5 inscriptions clés dans la nouvelle catégorie de cartouches de vapotage de la SQDC, y compris des cartouches de vapotage à base de rosine vivante à venir
24/07/2025 -
Cannara Secures 5 Key Listings in Québec’s New Vape Cartridge Category Including to be Released Live Rosin Vapes
24/07/2025 -
Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy
24/07/2025 -
The Joint Corp. to Host Conference Call on Thursday, August 7th to Discuss Second Quarter 2025 Results
24/07/2025 -
Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study
24/07/2025 -
Regeneron Announces the 2025 Winners of the Regeneron Prize for Creative Innovation
24/07/2025 -
Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus
24/07/2025
Pages